Vault-13

Venrock Adviser, LLC

NEW YORK, NY · CIK 1615982 · 13F filing filed 2022-05-16

SEC-registered investment adviser since 2014 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 11
Palo Alto, CAUnited States United States

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$617.2m reported value -15.6% vs Q4 2021
27positions
74.3%in top 10
6 new 3 added 2 reduced 5 sold out vs Q4 2021

Holdings, Q1 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ACLARIS THERAPEUTICS INC COM ACRS ACRS 4,563,962 $78.7m12.75% 12.75% UnchangedShares held: Q2 2021 4.6m, Q3 2021 4.6m, Q4 2021 4.6m, Q1 2022 4.6m
2 INSTIL BIO INC COM COM 6,865,076 $73.8m11.96% 11.96% UnchangedShares held: Q2 2021 6.9m, Q3 2021 6.9m, Q4 2021 6.9m, Q1 2022 6.9m
3 RELMADA THERAPEUTICS INC COM RLMD RLMD 2,270,072 $61.3m9.93% 9.93% UnchangedShares held: Q2 2021 1.4m, Q3 2021 1.4m, Q4 2021 2.3m, Q1 2022 2.3m
4 TRAVERE THERAPEUTICS INC COM TVTX TVTX 1,994,997 $51.4m8.33% 8.33% UnchangedShares held: Q2 2021 0, Q3 2021 1.7m, Q4 2021 2.0m, Q1 2022 2.0m
5 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 2,051,060 $37.5m6.08% 6.08% AddedShares held: Q2 2021 1.3m, Q3 2021 1.6m, Q4 2021 2.0m, Q1 2022 2.1m +29.1k +29,075 1.4%
6 TRICIDA INC COM TCDA TCDA 4,494,851 $36.9m5.99% 5.99% AddedShares held: Q2 2021 0, Q3 2021 390.7k, Q4 2021 3.5m, Q1 2022 4.5m +1.0m +1,000,000 28.6%
7 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 1,852,919 $34.3m5.55% 5.55% UnchangedShares held: Q2 2021 19.5k, Q3 2021 19.5k, Q4 2021 1.9m, Q1 2022 1.9m
8 MARINUS PHARMACEUTICALS INC COM NEW MRNS MRNS 3,156,803 $29.5m4.78% 4.78% AddedShares held: Q2 2021 2.6m, Q3 2021 2.6m, Q4 2021 2.9m, Q1 2022 3.2m +276.7k +276,707 9.6%
9 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 865,116 $29.5m4.77% 4.77% UnchangedShares held: Q2 2021 1.2m, Q3 2021 1.1m, Q4 2021 865.1k, Q1 2022 865.1k
10 AADI BIOSCIENCE INC COM WHWK WHWK 1,529,402 $26.0m4.20% 4.20% UnchangedShares held: Q2 2021 0, Q3 2021 1.5m, Q4 2021 1.5m, Q1 2022 1.5m
11 CHINOOK THERAPEUTICS INC COM ADRO ADRO 1,283,821 $21.0m3.40% 3.40% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 1.3m, Q1 2022 1.3m
12 LIANBIO SPONSORED ADS LIANY LIANY 5,378,341 $20.0m3.23% 3.23% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 5.4m, Q1 2022 5.4m
13 VISTAGEN THERAPEUTICS INC COM NEW VTGN VTGN 16,047,286 $19.9m3.22% 3.22% UnchangedShares held: Q2 2021 16.0m, Q3 2021 16.0m, Q4 2021 16.0m, Q1 2022 16.0m
14 ATHIRA PHARMA INC COM COM 1,000,000 $13.5m2.19% 2.19% UnchangedShares held: Q2 2021 1.5m, Q3 2021 1.2m, Q4 2021 1.0m, Q1 2022 1.0m
15 EIGER BIOPHARMACEUTICALS INC COM CLDN CLDN 1,469,767 $12.2m1.98% 1.98% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 1.5m
16 NUVALENT INC COM COM 803,951 $11.2m1.81% 1.81% UnchangedShares held: Q2 2021 0, Q3 2021 804.0k, Q4 2021 804.0k, Q1 2022 804.0k
17 GRAPHITE BIO INC COM GRPH GRPH 1,612,617 $8.2m1.33% 1.33% UnchangedShares held: Q2 2021 1.6m, Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m
18 PROVENTION BIO INC COM PRVB PRVB 1,118,653 $8.2m1.33% 1.33% NewShares held: Q2 2021 2.9m, Q3 2021 0, Q4 2021 0, Q1 2022 1.1m
19 COGENT BIOSCIENCES INC COM COGT COGT 1,088,817 $8.2m1.32% 1.32% UnchangedShares held: Q2 2021 1.1m, Q3 2021 1.1m, Q4 2021 1.1m, Q1 2022 1.1m
20 ATYR PHARMA INC COM NEW ATYR ATYR 1,398,889 $7.5m1.21% 1.21% ReducedShares held: Q2 2021 0, Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.4m -166.1k -166,111 -10.6%
21 AFFIMED N V COM COM 1,428,571 $6.2m1.01% 1.01% UnchangedShares held: Q2 2021 0, Q3 2021 0, Q4 2021 1.4m, Q1 2022 1.4m
22 SIERRA ONCOLOGY INC COM NEW COM NEW 162,479 $5.2m0.84% 0.84% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 162.5k
23 ALTIMMUNE INC COM NEW ALT ALT 759,719 $4.6m0.75% 0.75% NewShares held: Q2 2021 3.5m, Q3 2021 3.8m, Q4 2021 0, Q1 2022 759.7k
24 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 411,361 $3.7m0.60% 0.60% ReducedShares held: Q2 2021 1.1m, Q3 2021 1.1m, Q4 2021 1.1m, Q1 2022 411.4k -715.9k -715,911 -63.5%
25 ASTRIA THERAPEUTICS INC COM CATB CATB 538,999 $3.6m0.59% 0.59% UnchangedShares held: Q2 2021 0, Q3 2021 539.0k, Q4 2021 539.0k, Q1 2022 539.0k
26 AEROVATE THERAPEUTICS INC COM COM 151,037 $2.8m0.45% 0.45% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 151.0k
27 SAVARA INC COM SVRA SVRA 1,905,265 $2.5m0.40% 0.40% NewShares held: Q2 2021 0, Q3 2021 0, Q4 2021 0, Q1 2022 1.9m

Sold out since Q4 2021

SecurityTickerShares held beforeValue then
KINNATE BIOPHARMA INC KNTE KNTE 773,014 $13.7m773.0k shares
OLEMA PHARMACEUTICALS INC OLMA OLMA 816,651 $7.6m816.7k shares
CVRX INC CVRX CVRX 533,370 $6.5m533.4k shares
AKOYA BIOSCIENCES INC AKYA AKYA 400,000 $6.1m400.0k shares
CORVUS PHARMACEUTICALS INC CRVS CRVS 250,000 $603.0k250.0k shares